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Frontotemporal dementia (FTD) is a highly heritable condition with multiple genetic causes. In this study,
similarities and differences of gray matter (GM) atrophy patterns were assessed among 3 common forms
of genetic FTD (mutations in C9orf72, GRN, and MAPT). Participants from the Genetic FTD Initiative
(GENFI) cohort with a suitable volumetric T1 magnetic resonance imaging scan were included (319): 144
nonmutation carriers, 128 presymptomatic mutation carriers, and 47 clinically affected mutation carriers.
Cross-sectional differences in GM volume between noncarriers and carriers were analyzed using voxel-
based morphometry. In the affected carriers, each genetic mutation group exhibited unique areas of
atrophy but also a shared network involving the insula, orbitofrontal lobe, and anterior cingulate. Pre-
symptomatic GM atrophy was observed particularly in the thalamus and cerebellum in the C9orf72
group, the anterior and medial temporal lobes in MAPT, and the posterior frontal and parietal lobes as
well as striatum in GRN. Across all presymptomatic carriers, there were signiﬁcant decreases in the
anterior insula. These results suggest that although there are important differences in atrophy patterns
for each group (which can be seen presymptomatically), there are also similarities (a fronto-insula-
anterior cingulate network) that help explain the clinical commonalities of the disease.
 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).tre, Department of Neurode-
Square, London WC1N 3BG,
E-mail address: j.rohrer@ucl.ac.uk (J.D. Rohrer).
1 List of consortium members in appendix.
Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
D.M. Cash et al. / Neurobiology of Aging 62 (2018) 191e1961921. Introduction review boards for each of the GENFI sites, with every participant
providing written informed consent.Frontotemporal dementia (FTD) is a common cause of dementia
with around one-third of cases being familial, most commonly
caused by mutations in 1 of 3 genes: chromosome 9 open reading
frame 72 (C9orf72), progranulin (GRN), and microtubule-associated
protein tau (MAPT) (Rohrer et al., 2009). Studying mutation carriers
in the years before any signs of clinical manifestation provides
insight into the early stage of the disease process. One biomarker of
particular interest in presymptomatic FTD is brain atrophy as
measured by structural magnetic resonance imaging (MRI).
Although there have been many studies describing the atrophy
patterns in FTD (Mahoney et al., 2012; Rohrer et al., 2010; Whitwell
et al., 2009, 2012), these have commonly been smaller single-site
studies of patients who are already symptomatic. The multicenter
Genetic FTD Initiative (GENFI) investigates both affected and at-risk
FTD family members, with preliminary region of interest (ROI)
based cross-sectional analysis indicating that carriers have signiﬁ-
cantly lower cortical and subcortical volumes a number of years
before the expected age at onset (Rohrer et al., 2015). In this study,
we use data from GENFI to perform a whole-brain voxel-wise
analysis to provide complementary information to the previous ROI
study and expand on previous voxel-based morphometry studies in
genetic FTD, with a particular focus on comparing and contrasting
patterns of atrophy between the mutations and determining the
extent of gray matter loss in the presymptomatic phase.2. Material and methods
2.1. Participants
At the time of the second data freeze in the GENFI study, 365
participants had been recruited across 13 centers in the United
Kingdom, Canada, Italy, Netherlands, Sweden, and Portugal, of
whom 319 had a usable volumetric T1-weighted MRI scan for
analysis (15 participants did not have a scan, and a further 31 par-
ticipants were excluded as the scans were of unsuitable quality due
to motion, other imaging artifacts, or pathology unlikely to be
attributed to FTD). All participants were known to be a symptom-
atic carrier of a pathogenic mutation in C9orf72, GRN, orMAPT or to
be an at-risk ﬁrst-degree relative. Patients were considered symp-
tomatic when the assessing clinician felt that the patient had evi-
dence of progressive cognitive or behavioral change. All
participants underwent genetic testing to determine whether they
were a carrier or noncarrier: in total, 144 were noncarriers, 128
were presymptomatic mutation carriers, and 47 were affected
mutation carriers (Table 1). All participants underwent a stan-
dardized clinical assessment as described previously (Rohrer et al.,
2015). All aspects of the study were approved by the institutionalTable 1
Demographics of participants included in the analysis
Variable Noncarriers C9orf72 GRN
Presymptomatic Affected Presymptomatic Affe
N 144 40 25 65 1
Age, mean (SD) 48.7 (14.3) 43.5 (10.5) 65.2 (7.7) 48.9 (10.7) 63.2
%Female 63 63 28 63 6
EYO, mean (SD) 10.5 (14.2) 15.0 (12.5) 5.8 (5.0) 10.3 (11.3) 1.4
Education, y 13.8 (3.4) 13.9 (3.0) 13.1 (4.5) 14.1 (3.1) 10
Disease duration, y N/A N/A 6.6 (4.8) N/A 2.5
MMSE (max ¼ 30) 29.2 (1.3) 29.2 (1.2) 24.8 (4.2) 29.1 (1.4) 20.7
Diagnoses in affected subjects: bvFTD 33 (18 C9orf72, 5 GRN, 10 MAPT), 3 FTD-ALS (all C9
semantic variant PPA (C9orf72), 1 corticobasal syndrome (GRN), 1 dementia - not otherw
Bold text indicates a statistically signiﬁcant difference (p< 0.05) between groups.2.2. MR image acquisition
Participants underwent a 1.1-mm isotropic resolution volu-
metric T1 MR imaging on a 3T scanner (10 sites: 5 Siemens Trio,
1 Siemens Skyra, 3 Philips Achieva, 1 GE Discovery MR750) or 1.5T
scanner (1e1.25 mm isotropic resolution) when a 3T scanner was
not available (3 sites: Siemens Avanto, Siemens Aera, GE Signa
HDxt).
All analyses were performed using the Statistical Parametric
Mapping toolbox (SPM12) in Matlab. The images were ﬁrst
segmented intomaps representing probability of graymatter, white
matter, and cerebrospinal ﬂuid at each voxel (Ashburner and
Friston, 2005). Next, all images were spatially normalized using
geodesic shooting (Ashburner and Friston, 2011) to a study speciﬁc
template, modulating the probability maps to preserve tissue vol-
umes. Thewarped andmodulated tissuemaps were smoothedwith
a Gaussian kernel of full width at half max of 6 mm to reduce errors
caused by misalignment while at the same time allowing for
detection of differences over small regions of the brain. Analysis
was limited to a gray matter mask that included voxels where the
mean probability of the gray matter mask over all subjects was 0.2
or above. Estimates of total intracranial volume were computed by
summing the 3 tissue class volumes (Malone et al., 2014).
2.3. Statistical analysis
Baseline demographic variables were compared across groups
using a Kruskal-Wallis test for the continuous variables and a
Fisher’s exact test for gender. Three tests were performed: across all
groups, across the at-risk groups (noncarriers and presymptomatic
mutation carriers), and across the affected groups.
Data at each voxel of the smoothed, warped, andmodulated gray
matter (GM) maps were ﬁtted to a general linear model. We
implemented 2 models, subdividing the carriers into more distinct
subgroups with each level. In model 1, a 3-level factor was used:
nonmutation carriers, presymptomatic mutation carriers, and
affected carriers. Model 2 further subdivided the carrier subgroup
to create a 7-level factor: noncarriers, presymptomatic and affected
C9orf72 carriers, presymptomatic and affected GRN carriers, and
presymptomatic and affected MAPT carriers. All models included a
factor variable for imaging site and covariates for age, gender, and
total intracranial volume. As it was expected thatmembers from the
same family enrolled in GENFI might have covariance in brain
structure, family membership was included in the model as a
random effect.
Contrasts were performed to look at the following pairwise
differences: in model 1, noncarriers with presymptomatic carriersMAPT p-value
cted Presymptomatic Affected All groups At-risk groups
(including noncarriers)
Affected
groups
2 23 10 - - -
(6.0) 38.6 (9.0) 57.2 (5.9) <0.001 <0.001 0.011
7 61 30 0.021 1.000 0.083
(2.1) 11.8 (10.3) 5.9 (3.5) <0.001 0.270 0.001
(3.8) 13.4 (3.4) 12.2 (4.7) 0.040 0.788 0.125
(1.3) N/A 4.9 (5.3) N/A N/A 0.010
(6.2) 29.4 (1.4) 24.7 (4.9) <0.001 0.359 0.139
orf72), 7 nonﬂuent variant primary progressive aphasia (PPA) (2 C9orf72, 5, GRN), 1
ise speciﬁed (C9orf72).
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with each of the 6 carrier groups, as well as comparisons between
the 3 mutations within the presymptomatic and affected groups
separately. In model 2, we combined the 3 contrasts between
noncarriers and each of the affected carrier subgroups to construct
a compound hypothesis, where the null hypothesis was that 2 or
less contrasts were signiﬁcant. Signiﬁcant ﬁndings from the com-
pound hypothesis indicate GM atrophy patterns that are common
to all 3 genetic mutations. To correct for the multiple comparisons
problem inherent in mass univariate statistical analysis, we
controlled for voxel-level family-wise error (FWE) at p < 0.05. If
results did not reach signiﬁcance after correction for multiple
comparisons, we describe patterns at an uncorrected level of p <
0.001. Findings were reported with a cluster extent greater than the
empirically determined threshold provided by SPM (the expected
voxels per cluster, k ¼ 56 voxels, 190 mm3).3. Results
3.1. Demographics variables
Baseline demographic variables are shown in Table 1. Across all
groups, there are signiﬁcant differences in all variables. These
ﬁndings are primarily driven by differences between the at-riskFig. 1. Gray-matter (GM) differences by mutation and clinical status. GM differences in affe
uncorrected) carriers compared to noncarriers. Comparisons to the C9orf72 carriers are in th
group), the GRN carriers in the middle 2 rows, and MAPT carriers in the bottom 2 rows.groups and the affected groups. When comparing the at-risk
groups, only signiﬁcant differences in age remained, with the
noncarriers and presymptomatic GRN carriers being older than the
C9orf72 and MAPT carriers. When comparing only the affected
groups, differences remained in age, estimated years to onset, and
the disease duration as determined by the participant’s actual
onset. MAPT carriers were younger than the other 2 mutations,
while affected GRN carriers had lower estimated years to onset and
disease duration.3.2. Symptomatic mutation carriers
Comparison of all affected mutation carriers (GRN, MAPT, and
C9orf72 combined) with noncarriers shows widespread decrease in
GM, with the most signiﬁcant areas in the orbitofrontal and inferior
frontal lobes, temporal lobes (anterior > posterior), insula, anterior
cingulate, parietal lobe (around the precuneus), and cerebellum
(eTable 1 and eFig. 1).
Looking at the affected mutation carriers in each individual
mutation, different but overlapping patterns of atrophy were seen
(eTable 2, Figs. 1 and 2). In C9orf72 carriers, there were signiﬁcant
areas of GM loss throughout the brain including the frontal (orbi-
tofrontal > dorsolateral/ventromedial prefrontal), temporal (infe-
rior > superior), insula (anterior > posterior), and cingulate (bothcted (odd rows, p < 0.05 FWE-corrected) and presymptomatic (even rows, p < 0.001
e top 2 rows (with ﬁndings at p < 0.05, FWE-corrected circled in the presymptomatic
D.M. Cash et al. / Neurobiology of Aging 62 (2018) 191e196194anterior and posterior) regions as well as more posterior cortical
areas (precuneus and inferior > superior parietal regions).
Subcortical structures were particularly affected, most signiﬁcantly
the thalamus but also the hippocampus, amygdala, and basal
ganglia. GM loss was also seen in the cerebellum, affecting the
superior posterior area most signiﬁcantly (Fig. 1). Signiﬁcant GM
atrophy was seen in the affected GRN carriers in the frontal lobe
(particularly in the dorsolateral and ventromedial prefrontal
cortices), insula, anterior cingulate, superior and middle temporal
gyri and striatum (caudate and putamen) as well as more posteri-
orly in the lateral and medial parietal lobes (precuneus). Affected
MAPT carriers had signiﬁcant atrophy in the hippocampus, amyg-
dala, and temporal lobes (particularly anterior, medial, and inferior)
as well as the insula and orbitofrontal lobe. Direct comparisons
between affected mutation groups are shown in eTable 2.
Fig. 2 summarizes the similarities and differences in GM atrophy
within the 3 mutations. The blue (C9orf72), green (GRN), and red
(MAPT) regions are areas where only that speciﬁc mutation had
evidence of signiﬁcant GM atrophy in the affected carriers (p< 0.05,
FWE-corrected). Thalamic, superior cerebellar and very posterior
cortical involvement (particularly inferior parietal lobe) is unique to
C9orf72; superior aspect of the dorsolateral frontal cortex, dorso-
lateral caudate, and superior parts of the medial parietal regions are
only affected in GRN; and anteroinferior temporal lobe involvement
is unique to MAPT. In contrast, the ﬁndings from the compound
hypothesis indicate the atrophy pattern common to all 3 mutations
(light pink), which comprises a network of regions encompassing
mainly the insula, orbitofrontal lobe, and anterior cingulate
bilaterally.Fig. 2. Comparison of gray matter atrophy patterns across the 3 genetic mutations. Compar
hand of the ﬁgure, masks of the regions where there are signiﬁcant differences (p < 0.05, FW
intersect within 2 or more mutations. The region satisfying the compound hypothesis of all 3
in light pink. A surface rendering of this intersection is shown on the right. (For interpreta
version of this article.)3.3. Presymptomatic mutation carriers
When comparing the combined group of presymptomatic car-
riers to noncarriers, signiﬁcant areas of GM loss are seen in the
anterior insula when correcting for multiple comparisons
(eTable 1), with further regions (uncorrected for multiple compar-
isons) of GM loss in the orbitofrontal lobe, anterior temporal lobe,
posterior insula, parietal lobe and thalamus.
In the individual subgroups of presymptomatic mutation car-
riers (in comparison with noncarriers) the areas of GM atrophy
were similar to those seen in the affected cases but to a lesser extent
(Fig. 1, eTable 3). In C9orf72 carriers there were signiﬁcant areas of
GM loss bilaterally in the thalamus, right superior posterior cere-
bellum (Crus I), superior temporal and inferior frontal regionswhen
correcting for multiple comparisons, with more extensive loss in
the same areas as well as the anterior insula, temporal (including
hippocampi and amygdala), and parietal (particularly inferiorly)
regions at an uncorrected p-value of <0.001 (as shown in Fig. 1). In
GRN and MAPT carriers no areas survived correction for multiple
comparisons, but at an uncorrected signiﬁcance level, areas of GM
atrophy were seen in GRN carriers in the insula, parietal, posterior
frontal and anterior temporal lobes as well as the striatum (Fig. 1,
eTable 3), and inMAPT carriers in the anterior and medial temporal
lobes (including hippocampus and amygdala) and the orbitofrontal
lobe (Fig. 1, eTable 3). Direct comparisons betweenmutation groups
are shown in eTable 3.
As there have been reports in the familial AD literature of
increased volume in brain structures prior to atrophy (Fortea et al.,
2010; Lee et al., 2012), we performed reverse contrasts looking forison of atrophy patterns across the 3 genetic groups (symptomatic carriers). On the left
E-corrected) are shown, color coded by mutation, along with areas where the patterns
contrasts being true, indicating the intersection of atrophy in these mutations, is coded
tion of the references to color in this ﬁgure legend, the reader is referred to the Web
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noncarriers. In each of these tests, there were no ﬁndings of GM
increase, even at an uncorrected level of p < 0.001, within any
affected or presymptomatic group.
4. Discussion
Using a whole-brain voxel-wise analysis of gray matter volume
in a genetic FTD cohort, we show evidence of unique areas of at-
rophy in each mutation with an intersecting region of atrophy
affecting all 3 mutation groups in the insula, orbitofrontal lobe, and
anterior cingulate. Analysis of presymptomatic carriers shows evi-
dence of atrophy before symptom onset in each of the mutation
groups. This work expands on previous studies, which have inves-
tigated smaller cohorts, commonly at a single site and primarily
focusing on differences in affected patients.
Findings in symptomatic mutation carriers are consistent with
atrophy signatures found in previous voxel-based morphometry
studies of genetic FTD (Mahoney et al., 2012; Rohrer et al., 2010;
Whitwell et al., 2009, 2012). In MAPT mutation carriers, atrophy
primarily affects the anterior and medial temporal lobes, orbito-
frontal lobe and insula; in GRNmutation carriers atrophy is found in
the dorsolateral and ventromedial prefrontal, superolateral tem-
poral and lateral parietal lobes as well as the anterior cingulate,
insula, precuneus and striatum; whilst in C9orf72mutation carriers
there is relatively widespread cortical atrophy including posterior
areas, and particularly affecting the thalamus and superoposterior
cerebellum. Importantly, in this study, we show through a com-
pound hypothesis of contrasts in the general linear model that
there are common regions of atrophy across all 3 genes in the
orbitofrontal lobe, insula, and anterior cingulate. Interestingly, this
area overlaps substantially with the so-called salience network
(Seeley et al., 2007), an intrinsic connectivity network, described as
being fundamentally involved in FTD (Filippi et al., 2013; Seeley
et al., 2009; Zhou et al., 2010). It is this neuroanatomical corre-
spondence, which likely accounts for the overlapping behavioral
clinical syndrome seen in the majority of cases of genetic FTD.
The ﬁndings in the presymptomatic carriers add to the region of
interest results in the initial GENFI study and other presymptomatic
studies (Bocchetta et al., 2016; Rohrer et al., 2015; Whitwell et al.,
2012). The strongest evidence of presymptomatic atrophy was
observed in C9orf72 carriers in the thalamus and superoposterior
cerebellum. A recent study of 15 presymptomatic C9orf72 carriers
(Lee et al., 2017) also found decreased GM compared to noncarriers
in the left thalamus but did not show any differences in the cere-
bellum. Uncorrected ﬁndings of atrophy were observed in MAPT
mutation carriers in the anteromedial temporal and orbitofrontal
lobes, and in striatum, frontal, temporal, and parietal areas of GRN
carriers. However, when pooling all presymptomatic carriers in
model 1, there was signiﬁcant evidence of atrophy surviving FWE
correction for multiple comparisons in the right anterior insula.
These results indicate that there may be some distinct regions in
which the disease process starts, but those common sites across all
3mutationsmay also be involved during the presymptomatic phase
of the disease.
There is relatively minimal atrophy in presymptomatic GRN
carriers. The explanation for this ﬁnding is unclear. It is unlikely to
represent a difference in the age or expected proximity to onset of
the GRN presymptomatic cohort compared to the other genes but
could be indicative of atrophy occurring nearer to symptom onset in
GRN-related FTD. A longitudinal study of cortical thickness in 16
presymptomatic GRN carriers (Caroppo et al., 2015) found no cross-
sectional differences at baseline compared to 17 noncarriers, but
longitudinal changes over 20-month follow-up were observed in 1
cluster in the middle and inferior temporal gyrus. This cluster wasnot found in our presymptomatic GRN carriers, but it was present in
the affected participants. This could be consistent with the patho-
physiological process that occurs in GRN, where an additional insult
or injury (superimposed on low progranulin levels) is likely to be
required to start the neurodegeneration process with more rapid
GM loss (and sooner onset of symptoms) subsequently (Martens
et al., 2012; Rohrer et al., 2010; Yin et al., 2009). It could also be
in part due to the noted asymmetric atrophy in these cases, which
can variably affect the right or left hemisphere (Le Ber et al., 2008;
Rohrer et al., 2010). In MAPT mutation carriers, the ﬁndings in the
presymptomatic group closely mirror those found in the affected
carriers (Fig. 2, bottom 2 rows), and although not reaching signiﬁ-
cance once correcting for multiple comparisons, the pattern is
similar to that of symptomatic cases but to a lesser extent.
In all 3 at-risk groups, it will be important to investigate the
GENFI cohort in more detail when a larger cohort is available who
can be further stratiﬁed by age (or expected time to symptom
onset). The current presymptomatic cohort represents a heteroge-
neous sample with 39 (9 C9orf72, 22 GRN, 8 MAPT) of 130 partici-
pants within 5 years of their expected age at onset, when atrophy is
more likely to be present, while 33 participants (12 C9orf72, 15 GRN,
and 6 MAPT) are more than 20 years away from expected onset,
where atrophy should be minimal.
In summary, we were able to observe distinct but overlapping
patterns of GM atrophy between carriers of key mutations known
to cause FTD with similar patterns (albeit to a lesser extent) seen
during the presymptomatic phase. We found decreases in gray
matter in presymptomatic participants that survived stringent
correction for multiple comparisons: both within C9orf72 carriers
in the thalamus, cerebellar crus, frontal, and temporal lobes, as well
as in the anterior insula across all presymptomatic carriers. Further
studies are required not only to increasingly stratify the presymp-
tomatic cohort but also of other imaging modalities including
diffusion tensor imaging and resting-state functional MRI to un-
derstand how the GM regions identiﬁed in this study are struc-
turally and functionally connected, allowing insight into the earliest
involved areas in genetic FTD and how disease propagates from
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